PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'School of Pharmacy, Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, 192-0392, Japan.\', \'Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba 305-0801, Japan.\', \'Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan.\', \'Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn 53121, Germany.\', \'School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.\', \'Pharmaceutical Institute, Pharmaceutical/Medicinal Chemistry, University of Tübingen, Tübingen 72076, Germany.\', \'Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Koto, Tokyo 135-0064, Japan.\', \'Faculty of Medicine, Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan.\', \'Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1021/acs.jmedchem.1c00665
?:doi
?:hasPublicationType
?:journal
  • Journal of medicinal chemistry
is ?:pmid of
?:pmid
?:pmid
  • 34313428
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.567
?:rankingScore_hIndex
  • 231
?:title
  • 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all